Mark Day Ph.D., President & CEO:
Dr. Day is currently an Associate Professor of Neuroscience at Yale University. Most recently he served as Head, CNS Virtual Discovery at Purdue Pharma. Prior to joining Purdue, Dr. Day served as Executive Director, Head of External Research & Scouting at Alexion Pharmaceuticals, Inc. In this role he established the team, developed the business strategy and worked to get the endorsement of a venture fund. Prior to this, he led CNS Business Development at BMS and was the responsible for the identification, evaluation and facilitated the acquisition of iPierian for their humanized monoclonal Tau antibody for the treatment of Progressive Supra Nuclear Palsy, which has since been acquired by Biogen.
Mark also served as the Head of Translational Imaging and Biochemical Biomarkers at Abbott Labs, and led Wyeth’s CNS translational medicine research. During this tenure Mark identified and implemented 17 research and development collaborations.
His PhD was conducted at Cardiff University, and his Post Doctoral studies were under Professor RG Morris at The University of Edinburgh. He has published over 60 peer reviewed journal articles (e.g. Nature, Science, Nature Neuroscience, Neuroimaging etc.) and has been successful in identifying the best ways to optimize and mobilize internal and external resources to ensure the building of highly motivated and effective teams.
Ms. Judi Dalling LLB: CFO
Judi Dalling is a lawyer with experience in corporate and securities law. She also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
Dr. Reinhard Gabathuler: Chief Scientist
Reinhard has over 25 years experience in research in academia and in early stage development companies (start-ups) and a broad knowledge of scientific research from Plant Biochemistry to Immunology, Oncology and Neurology. He has been very successful in a research results driven environment and is a strong leader with planning and interpretation skills acquired in early stage biotechnology companies.
Dr. Mei Mei Tian: Vice President, Head of External Research
Dr. Tian has over 10 years experience working on Melanotransferrin related research in both academia and biotech. With her oncology and neurology backgrounds she has been a significant contributor in the early development and continued expansion of our second generation Transcend technology, MTfp. She is a committed and driven individual with a passion for the success of our Transcend technology.